The science, business and culture of living longer and better; from healthspan research to the emerging longevity economy.
15 articles
Northwestern, Weill Cornell and Mayo Clinic now sell cash-pay longevity programmes at up to $45,000 a year. Of the four motives behind them, the most telling sits on Weill Cornell's FAQ: proving clinical value so insurers eventually pay, which turns the paying patient into a trial participant who pays instead of being paid.
The longevity vocabulary ladder (prevention, healthspan, hotspan, sexspan, peakspan) is a live map of where the money moves. Each -span is born at the top of the market as a scarcity product, while AI platforms like Midi democratise the knowledge layer beneath it, so abundance and scarcity stack instead of alternating.
Dubai's Law No. 17 of 2026 created a Longevity Authority chaired by the emirate's economy chief, not a health minister, turning a decade-old 'region as regulated test centre' thesis into live policy. The piece asks why Europe still files ageing under cost while the Gulf builds it into a sovereign export industry.
The fitness industry spent three years running healthcare's experiment for it: hand millions of people wearables, AI and data, then watch what changes behaviour. The result is that the data became the commodity and the human who turns it into behaviour became the premium, exactly the high-touch role healthcare keeps trimming while it funds the high-tech half.
Sixty percent of UK workers now rank private health insurance as their most valued workplace benefit, ahead of extra holiday. That single inversion breaks the century-old logic of employee benefits, and makes most of the 2026 perks stack retention-irrelevant for the people companies most want to keep.
Q1 2026 marked a convergence in longevity: $3.74B raised, 173 AI-discovered drugs in trials, the first FDA-approved mitochondrial therapy, and a 71% jump in global events. The sector's bottleneck is no longer discovery; it's whether clinical practice can absorb what's coming.
We've given healthcare AI the most powerful memory technology ever built, then asked it to forget everything at the end of each appointment. Three major acquisitions in January 2026 suggest the industry is finally asking the right question.
An AI system designed a drug from scratch that just hit Phase 1 trials. The real story isn't the molecule — it's the swarm of agents that built it.
Your GP sees you twice a year; your skincare routine sees you twice daily. As L'Oréal maps 260+ longevity biomarkers, Beiersdorf launches an 'Age Clock' and Unilever links the microbiome to visible ageing, beauty brands are quietly becoming health platforms, raising hard questions about data portability, duty of care, and who owns your epigenome.
Formula One taught us that optimising machines requires engineers, not just drivers. Rejuve AI's Infinite Games 2026 in Honduras is testing what happens when human biology becomes the machine: over 100 athletes competing whilst comprehensive biomarker data tracks biological ageing in real-time.
Solar panels dropped 99% in price over five decades. LED bulbs fell 95% in 14 years.
What will employees demand from employers in 10 or 15 years, once benefits move beyond wellness apps and into the fabric of biology itself? A look at the biological arms race for talent, and the ethical tightrope it forces companies to walk.
What if hitting 60 felt like being 25 again? 💪 Explore how modern life is rewriting the rules of age and vitality.
Tesla started with a premium Roadster for early adopters, open-sourced its patents and sold direct to consumers. Five lessons from that playbook show how preventive healthcare could move faster from reactive care to proactive wellness, and fund broad access along the way.
As an avid trail runner with a passion for innovation, I have experimented extensively with various wearables, patches, and screenings, diligently recording the outcomes alongside my personal diaries.
